Gapping up
In reaction to strong earnings/guidance:
- N/A.
Other news:
- PFNX +13.8% (announces that the FDA has approved the new drug application for PF708, with Forteo as the reference drug, for the treatment of osteoporosis in certain patients at high risk for fracture)
- SPWR +5.9% (positively impacted by removal of tariff exemption for bifacial solar panels)
- FSLR +4.9% (positively impacted by removal of tariff exemption for bifacial solar panels)
- EDIT +2.2% (announce commercial license agreement)
- GE +1.9% (announces U.S. pension plan actions -- expected to reduce pension deficit by approximately $5-8 bln and net debt by approximately $4-6 bln)
- NBIX +1.4% (presents new data analyses demonstrating long-term effects of INGREZZA that show effectiveness in reducing abnormal movements in adults with tardive dyskinesia
- ENPH +1.3% (positively impacted by removal of tariff exemption for bifacial solar panels)
- TOT +1.3% (announced that the production from Phase 1 of the giant Johan Sverdrup field has started — more than two months ahead of schedule and with a cost reduced by more than 30%.)
- SCHW +1.1% (positive Barrons article)
- TSM +0.7% (positive Barrons article)
Analyst comments:
- RNG +5.5% (upgraded to Overweight from Neutral at JP Morgan)
- MTCH +4.2% (upgraded to Buy from Neutral at Nomura; upgraded to Buy from Hold at Deutsche Bank)
- SDC +3.6% (initiated with an Overweight at JP Morgan, among others)
- UBER +3.4% (upgraded to Buy from Neutral at Citigroup)
- AYX +2.5% (upgraded to Outperform from Neutral at Wedbush)
- ETFC +2.1% (upgraded to Buy from Neutral at UBS)